‘I Prep for Survival': OpenAI CEO Sam Altman Worries About The ‘Nonzero' Chance The World Will End From ‘a Lethal Synthetic Virus'
A Leader in Innovation and Caution
Altman's career demonstrates an unusual blend of technological optimism and caution. Since co-founding the social location app Loopt and serving as president of the influential startup incubator Y Combinator, Altman has been a driving force behind transformative companies like Airbnb, Stripe, and DoorDash. His move to OpenAI positioned him at the forefront of artificial intelligence, where rapid advancements have fueled both hope for progress and debate over associated perils.
More News from Barchart
Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses'
Why GOOGL Stock May Be the Market's Next Big Winner
Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued?
Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.
This dual outlook — a belief in technology's potential and awareness of its dangers — is central to Altman's leadership. As he influences the development of AI models now impacting millions globally, his concerns are not hypothetical. They spring from direct involvement in managing and mitigating emerging risks, including threats posed by biotechnology and synthetic biology.
Context for Concern: The H5N1 Case
Altman's reference to the Dutch lab's modification of the H5N1 bird-flu virus is rooted in a real scientific episode. In the early 2010s, researchers deliberately altered avian influenza to study its capacity for human transmission, sparking controversy and new anxieties about 'gain-of-function' research. This episode shifted expert discourse: the theoretical risk of engineered pandemics became more palpable, even if such events remain exceedingly rare.
For Altman, whose social circles reportedly include leading technologists and scientists, such discussions are not mere conjecture. They inform both his advocacy for responsible innovation and his personal preparedness mindset. These views resonate within the broader context of market and societal trends, where leaders are increasingly called to account for their roles in shaping risks, from cybersecurity to pandemic threats.
Authority Grounded in Experience
As the steward of OpenAI — a firm whose technologies could reshape economies and everyday life — Altman's authority on such matters is widely recognized. Regulators, investors, and fellow executives pay close attention when he speaks about future dangers, whether they arise from advanced AI, synthetic viruses, or other disruptive forces.
Altman's background in startup incubation, investment, and the management of frontier technologies has nurtured a deep understanding of the unpredictable intersections of science and society. His measured warnings about engineered biological risks, as well as other existential challenges, reflect not just personal caution but a broader ethos of vigilance that many now see as essential to responsible leadership in the technological age.
In a shifting landscape, Altman's pronouncements about nonzero risks carry weight both for their substance and their source — reminding markets, policymakers, and innovative communities that resilience begins with acknowledging hard realities as well as bold ambitions.
On the date of publication, Caleb Naysmith did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
21 minutes ago
- Wall Street Journal
Heard on the Street Recap: Done Deal
What Happened in Markets Today President Trump reached a trade deal with the EU. The deal imposes a 15% baseline tariff on products imported from the European Union to the U.S., including cars. The EU agreed to buy $750 billion of U.S. energy products and invest $600 billion in the U.S., Trump said. Stocks affected by the deal, including chip and auto companies, moved. Dutch semiconductor equipment manufacturer ASML, which recently flagged customer skittishness because of tariffs, rose 2.6% after the deal exempted its products from the levies. But car-makers slid, with BMW down 3.3% and Mercedes falling 3.2% in European trading. Market experts were also skeptical that the energy purchase targets would be achievable.
Yahoo
an hour ago
- Yahoo
What Are Wall Street Analysts' Target Price for AT&T Stock?
With a market cap of $198.6 billion, AT&T Inc. (T) is one of North America's largest wireless and communications service providers. The Dallas, Texas-based company operates through its Communications and Latin America segments, delivering wireless, broadband, and data services to over 240 million customers, reinforcing its position as a key player in the telecom industry. Shares of the telecom behemoth have notably outperformed the broader market over the past 52 weeks. T has soared 45% over this time frame, while the broader S&P 500 Index ($SPX) has gained 16.6%. Moreover, shares of T are up 20.4% on a YTD basis, compared to SPX's 8.3% rise. More News from Barchart Here's What Happened the Last Time Novo Nordisk Stock Was This Oversold Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock? Earnings Will Be 'Worse Than Expected' for UnitedHealth. How Should You Play UNH Stock Here? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Zooming in, AT&T has also surpassed the Communication Services Select Sector SPDR ETF Fund's (XLC) 25.7% rise over the past 52 weeks and 4.2% surge on a YTD basis. On July 23, AT&T reported strong Q2 results, highlighting growth driven by high-quality 5G and fiber subscriber additions. Revenue rose 3.5% year-over-year to $30.8 billion, and adjusted EPS beat expectations at $0.54. The company added 401,000 postpaid wireless subscribers and 243,000 fiber customers, supporting solid service revenue and earnings growth. T shares climbed 1.2% following the earnings release. For the current fiscal year, ending in December 2025, analysts expect T's adjusted EPS to decline 9.7% year-over-year to $2.04. The company's earnings surprise history is mixed. It beat the consensus estimates in three of the last four quarters while missing on another occasion. Among the 28 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on 17 'Strong Buy' ratings, three 'Moderate Buys,' seven 'Holds,' and one 'Strong Sell.' On July 24, Raymond James reaffirmed a "Strong Buy" rating on AT&T and raised its price target from $30 to $31, reflecting continued confidence in the stock's outlook and a 3.33% increase in projected valuation. AT&T's mean price target of $30.36 implies a modest 10.8% premium to current price levels, while the Street-high target of $34 suggests a staggering 24% upside potential. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
an hour ago
- Yahoo
Are Wall Street Analysts Bullish on CVS Health Stock?
With a market cap of $75.4 billion, CVS Health Corporation (CVS) is a leading U.S. healthcare company that operates across multiple segments, including retail pharmacies, pharmacy benefit management (PBM), and health insurance. Headquartered in Rhode Island, CVS owns one of the largest pharmacy chains in the country and also operates MinuteClinic walk-in clinics. Shares of the retail pharmacy titan have lagged behind the broader market over the past year. CVS stock has declined 2.6% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 16.6%. However, CVS has made a strong comeback in 2025, with its stock soaring 33.7% year-to-date, significantly outpacing the S&P 500's 8.3% gain over the same period. More News from Barchart Here's What Happened the Last Time Novo Nordisk Stock Was This Oversold Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock? Earnings Will Be 'Worse Than Expected' for UnitedHealth. How Should You Play UNH Stock Here? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Zooming in, CVS' stock has outperformed the iShares U.S. Healthcare Providers ETF (IHF), which has declined 25.4% over the past year and 12.6% on a YTD basis. On July 23, CVS Health shares soared 1.3% after the company announced the opening of its new Workforce Innovation and Talent Center (WITC) in Columbus, located at the Rosewind Community Center. In partnership with local organizations, the WITC offers free workforce training and health services, aiming to support careers in pharmacy, customer service, and retail. For the current fiscal year, ending in December 2025, analysts project CVS' EPS to grow 12.9% annually to $6.12 on a diluted basis. The company has a good track record of outperforming expectations, having surpassed the consensus estimate in each of the last four quarters. Among the 23 analysts covering CVS stock, the consensus rating is a 'Strong Buy.' That's based on 17 'Strong Buy' ratings, two 'Moderate Buys,' and four 'Holds.' This configuration has been consistent over the past months. On Jul. 22, UBS Group AG (UBS) lowered its price target on CVS Health from $71 to $67 while keeping a 'Neutral' rating, citing increased cost pressures in the Health Insurance Exchange and Medicaid segments. Despite these challenges, CVS maintains solid financial health and is considered undervalued, with potential offsets from cost-saving initiatives and acquisitions. The mean price target of $79.09 represents a 31.8% premium to CVS' current price levels. The Street-high price target of $95 suggests an upside potential of 58.3%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
